FerroKin BioSciences Gets $12M
FerroKin BioSciences, a San Francisco-based company seeking to treat iron overload, said today it has secured $12 million in venture financing. Existing investors Burrill & Co., Celgene, Clarus Ventures and MP Healthcare Venture Management, participated in the financing along with a new investor, Healthcap Ventures. The company says it has completed three clinical studies, in healthy volunteers and in patients with iron overload, to assess safety, absorption and metabolism of its oral pill, FBS0701. The company didn’t say in its statement what it plans to do with the money in further clinical development.